Verici Dx Plc (VRCI) AI Stock Analysis

• Market Cap: £9.46M
• Dividend Yield: N/A
• Average Volume (3M): 4.88M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.81
• Revenue Growth: -57.03%
• EPS Growth: -15.71%
• Country: UK
• Employees: 19
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 1,513,394,200
• 10 Day Avg. Volume: 7,932,443
• 30 Day Avg. Volume: 4,882,905
• PEG Ratio: 0.04
• Price to Book (P/B): 2.15
• Price to Sales (P/S): 3.38
• P/FCF Ratio: -1.82
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £0.50
• Price Target Upside: -35.90% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: 0.50p ▼(-35.90% Downside)

The overall stock score is primarily influenced by financial performance challenges, including ongoing losses and negative cash flows. Technical analysis provides some positive short-term momentum, but valuation remains a concern due to a negative P/E ratio and lack of dividend yield. The absence of earnings call data and corporate events means these factors do not influence the score.

Verici Dx Plc Business Overview & Revenue Model

Company Description

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.

How the Company Makes Money

Verici Dx Plc generates revenue primarily through the commercialization of its diagnostic tests aimed at assessing the risk of kidney transplant rejection. The company's revenue streams include sales of these proprietary tests to healthcare providers, including hospitals and clinics, that perform and manage kidney transplants. Verici Dx may also engage in partnerships or collaborations with pharmaceutical companies and research institutions to further develop its diagnostic technologies, which could contribute to additional revenue through licensing agreements or joint ventures. Moreover, the company might receive funding or grants to support its research and development efforts, aiding in the continuous improvement and expansion of its product offerings.

Verici Dx Plc Financial Statement Overview

Summary

Verici Dx Plc is experiencing revenue growth but continues to face profitability challenges, with ongoing net losses impacting return metrics. The balance sheet remains stable with low leverage, although cash flow issues persist due to negative operating cash flows, indicating the need for careful financial management and potentially further external financing.

Income Statement

Verici Dx Plc has shown a significant increase in total revenue from 2023 to 2024, indicating positive revenue growth. However, the company has consistently reported negative EBIT and net income figures, reflecting ongoing losses. The gross profit margin stands at 100% due to the absence of cost of goods sold, but negative net profit and EBIT margins highlight profitability challenges.

Balance Sheet

The company's balance sheet shows a strong equity position with a low debt-to-equity ratio, suggesting a conservative capital structure. However, the return on equity is negative due to net losses, which is a concern. The equity ratio indicates that a significant portion of the company's assets is financed by equity, which is a positive sign of financial stability.

Cash Flow

The cash flow statement reveals negative operating and free cash flow, indicating cash outflows from core operations. Financing activities have provided substantial cash inflows, suggesting reliance on external financing. The operating cash flow to net income ratio is negative, reinforcing cash flow challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.34M	1.01M	0.00	0.00	0.00
Gross Profit	3.34M	1.01M	0.00	0.00	0.00
EBITDA	-5.15M	-7.88M	-10.50M	-7.15M	-2.10M
Net Income	-5.87M	-8.73M	-11.36M	-8.33M	-7.10M
Balance Sheet
Total Assets	7.49M	7.44M	14.30M	13.79M	20.31M
Cash, Cash Equivalents and Short-Term Investments	4.06M	2.65M	9.80M	10.34M	17.75M
Total Debt	371.00K	540.00K	700.00K	0.00	73.55K
Total Liabilities	2.23M	3.88M	2.80M	1.80M	681.89K
Stockholders Equity	5.26M	3.56M	11.51M	11.98M	19.62M
Cash Flow
Free Cash Flow	-6.21M	-7.39M	-11.38M	-7.30M	-1.32M
Operating Cash Flow	-6.02M	-7.16M	-10.07M	-6.34M	-1.28M
Investing Cash Flow	61.00K	-231.00K	-1.31M	-965.86K	-237.16K
Financing Cash Flow	7.32M	-27.00K	12.67M	-73.55K	26.75M

Verici Dx Plc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.78
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VRCI, the sentiment is Positive. The current price of 0.78 is above the 20-day moving average (MA) of 0.66, above the 50-day MA of 0.58, and below the 200-day MA of 1.89, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 62.97 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:VRCI.

Verici Dx Plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABDX	59 Neutral	£11.62M	―	-62.83%	―	27.60%	1.35%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GDR	51 Neutral	£2.51M	―	-321.90%	―	125.37%	22.47%
BSFA	51 Neutral	£3.89M	―	-46.41%	―	-64.18%	12.05%
VRCI	49 Neutral	£9.46M	―	-122.54%	―	-57.03%	-15.71%
GENI	49 Neutral	£10.33M	―	-181.41%	―	12.12%	54.24%
PRM	41 Neutral	£5.37M	―	―	―	12.19%	18.12%

Verici Dx Plc Corporate Events

Verici Dx Showcases Tutivia™ Test at World Transplant Congress 2025

Verici Dx Plc announced the publication of several abstracts related to its Tutivia™ test ahead of the World Transplant Congress 2025. These abstracts highlight the test’s role in addressing unmet needs in transplant patient care, including managing BK nephropathy and obesity-related complications. The real-world evidence from multiple transplant centers underscores the test’s utility and supports its growing adoption, which is further bolstered by Medicare coverage.

Verici Dx Plc Raises £6.35 Million Through Successful Fundraising

Verici Dx Plc announced the successful completion of its WRAP Retail Offer, raising approximately £0.43 million at an issue price of 0.5 pence per share. This fundraising, combined with previous placements and subscriptions, has generated total gross proceeds of approximately £6.35 million, extending the company’s cash runway into the second half of 2026. The new shares are expected to be admitted to trading on AIM by 30 July 2025, increasing the company’s total ordinary share capital to over 1.5 billion shares. This financial boost is likely to enhance Verici Dx’s operational capabilities and strengthen its position in the clinical diagnostics market.

Verici Dx Launches Retail Offer to Raise £500,000

Verici Dx Plc has announced a retail offer to raise up to £500,000 through the issuance of new ordinary shares as part of its fundraising efforts. This follows a successful Placing and Subscription that raised approximately £5.92 million. The retail offer is open to eligible investors in the UK and aims to involve both new and existing shareholders. The proceeds from this offer will be used in the same manner as the previous fundraising, with the new shares expected to commence trading on AIM by the end of July 2025.

Verici Dx Raises £5.92 Million to Boost Transplant Diagnostics

Verici Dx Plc has successfully raised approximately £5.92 million through an oversubscribed placing and subscription, with significant participation from existing and new investors. The funds will be used to accelerate the commercial growth and scale-up of Tutivia™, enhancing patient outcomes for kidney transplant patients in the US. The company’s strategic fundraising efforts highlight its commitment to expanding its market presence and improving diagnostic accuracy in the organ transplant sector.

Verici Dx Announces £5 Million Fundraising for Transplant Diagnostics Expansion

Verici Dx Plc has announced a proposed equity fundraising to raise at least £5 million to support the commercial scale-up of its kidney transplant diagnostic tests. The fundraising involves a placing of new shares, a subscription by a US investor, and a retail offer, with the proceeds aimed at accelerating the company’s growth and enhancing its market position in transplant diagnostics.

Verici Dx Achieves Record Revenues and Expands Market Reach Amid Financial Challenges

Verici Dx reported record revenues of $3.3 million for 2024, driven by a commercial contract with Thermo Fisher for its PTRA test. The company achieved several operational milestones, including securing Medicare coverage for its Tutivia™ assay and receiving CLIA certification, which enhances its testing capabilities across the US. Despite financial challenges, including a need for additional funding by July 2025, Verici Dx is optimistic about its future growth, particularly in the post-transplant market, which is valued at approximately $900 million. The company aims to expand its market presence by addressing unmet needs in areas like delayed graft function and BK nephropathy.